PharmaCyte Biotech (PMCB) Change in Accured Expenses (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Change in Accured Expenses of $77175.0 for Q2 2026, down 94.33% year-over-year from $1.4 million in Q2 2025, and up 114.19% quarter-over-quarter from -$544000.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Change in Accured Expenses (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Change in Accured Expenses for 17 consecutive years, with $77175.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 94.33% year-over-year to $77175.0; the TTM figure through Apr 2026 stood at -$1.5 million (down 218.15% YoY), while the FY2026 annual figure was -$1.5 million, down 218.15% from the prior year.
- Change in Accured Expenses rose to $77175.0 in Q2 2026 per PMCB's latest filing, from -$544000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.4 million in Q2 2025 and bottomed at -$1.0 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged $24008.6 across 5 years, with a median of $15374.5 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2026.88% — and 2026, when it tumbled 54400100.0%.
- PharmaCyte Biotech's Change in Accured Expenses stood at -$80476.0 in 2022, then soared by 437.86% to $271896.0 in 2023, then sank by 96.69% to $9013.0 in 2024, then plunged by 932.13% to -$75000.0 in 2025, then jumped by 202.9% to $77175.0 in 2026.
- Business Quant data shows PMCB's Change in Accured Expenses at $77175.0 in Q2 2026, -$544000.0 in Q1 2026, and -$75000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 77,175.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 77,175.00 |
| Apr 30, 2026 | 77,175.00 |
| Jan 31, 2026 | -544,000.00 |
| Jan 31, 2026 | -544,000.00 |
| Oct 31, 2025 | -75,000.00 |
| Oct 31, 2025 | -75,000.00 |
| Jul 31, 2025 | -1.01 Mn |
| Jul 31, 2025 | -1.01 Mn |
| Apr 30, 2025 | 1.36 Mn |
| Apr 30, 2025 | 1.36 Mn |
| Jan 31, 2025 | 1.00 |
| Jan 31, 2025 | 1.00 |
| Oct 31, 2024 | 9,013.00 |
| Oct 31, 2024 | 9,013.00 |
| Jul 31, 2024 | -58,484.00 |
| Jul 31, 2024 | -58,484.00 |
| Apr 30, 2024 | 144,014.00 |
| Apr 30, 2024 | 144,014.00 |
| Jan 31, 2024 | -247,723.00 |
| Jan 31, 2024 | -247,723.00 |